New PNH Treatments

As we progress with PNH treatment options for patients, following successful clinical trials, we are pleased that now approved by NICE  for patients in England and Wales Iptacopan and Danicopan are now approved.

Iptacopan is an oral factor B inhibitor taken twice a day (monotherapy) and Danicopan is an add on oral factor D inhibitor taken three times a day with Eculizumab/Ravulizumab.

If you are eligible to switch to any of these treatments, this will be discussed with you in your clinic appointment.  Please see the treatment section on our website (coming soon) for more information .

If you live in Scotland or Northern Ireland, these are currently under review by the health authorities.